Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)

NCT01079234 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01079234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01079234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2010
Completion date
May 31, 2011
Enrollment
493 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 1